Second line treatment of hormone refractory prostatic cancer patients.
Collste
L G
LG
Department of Urology, Huddinge Universit Hospital, Karolinska Institute Medical School, Sweden.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D000970:Antineoplastic Agents; D006728:Hormones